NOVANTA INC quarterly report, Q1 FY2016

Business context and reporting period

GSI Group Inc. filed this unaudited Form 10-Q for the three months ended April 1, 2016, comparing results with the three months ended April 3, 2015. It designs and sells precision photonics and motion-control components and subsystems, primarily to OEMs in advanced industrial and medical markets. The filing identifies the registrant as GSI Group Inc.; this differs from the request metadata naming Novanta Inc. Verify the issuer identity and any subsequent corporate-name history before attributing these results.

Financial results and liquidity

Cash and cash equivalents were $67.9 million at April 1, 2016, up from $60.0 million at year-end 2015. Current assets were $195.4 million and current liabilities $60.3 million. Reported debt, net of unamortized issuance costs, was $94.2 million; the filing also reports $95.6 million of principal outstanding ($25.6 million term loans and $70.0 million revolver borrowings). The $175 million revolving facility had $105 million of unused availability. The facility matures in December 2017. The company was in compliance with covenants: actual leverage ratio 1.52 against a maximum 3.00, and fixed-charge coverage 3.72 against a minimum 1.50.

Net cash from investing activities was $1.7 million for continuing operations; total investing cash flow was $3.2 million including $1.5 million from discontinued operations. Financing activities used $3.4 million. The $2.3 million tax-free dividend from its 41%-owned Laser Quantum investment supported operating cash flow and reduced the effective tax rate.

Material changes versus the prior comparable period

• Revenue declined 4.5%; the company attributed 2.8 percentage points to acquisition/divestiture effects and 0.3 percentage points to foreign exchange, leaving an organic decline of 1.4%.
• Laser Products revenue fell 10.2%, including the impact of the JK Lasers divestiture and weaker CO2 laser demand. Vision Technologies revenue declined 7.2%, reflecting lower visualization sales, radiology-product discontinuation, and delays in surgical product introductions.
• Precision Motion revenue rose 13.7%, supported by acquisitions and demand for optical encoders; air-bearing spindle revenue weakened.
• Operating income fell 52.1%. Total gross profit declined $3.1 million, including a $1.6 million charge tied to discontinuing radiology products. Vision Technologies gross margin fell to 33.2% from 40.2%; total gross margin decreased 1.5 percentage points.
• Effective tax rate was 14.5%, versus 34.3% in the prior-year quarter, mainly reflecting income mix, discrete items, and the Laser Quantum dividend.

Outlook, commentary, risks and unusual items

• Management stated it expected operating cash flows to fund operating and capital needs for at least the next 12 months; unused revolver capacity was an additional liquidity source. This is management’s expectation, not a guarantee.
• The 2016 restructuring program, covering manufacturing consolidation and cost reductions, was expected to finish in Q2 2016. Cumulative costs were $5.6 million; management expected another $1.0–$1.6 million in charges.
• Management cited manufacturing-sector capital-spending weakness, customer qualification cycles, product-introduction delays, and demand fluctuations as factors affecting sales. Advanced industrial accounted for about 60% of revenue and medical about 40%.
• Other risks discussed include customer capital-spending cyclicality, execution and integration of acquisitions, restructuring disruption, foreign exchange and interest rates, supply interruptions, product issues, and access to subsidiary cash. Management reported no material change in risk factors from its 2015 Form 10-K.
• Legal claims arise in the ordinary course; management did not expect a material adverse effect, while noting outcomes cannot be assured. No material changes to purchase commitments or contractual obligations were reported.

Important facts for investors to verify

• Confirm issuer identity: the supplied filing is for GSI Group Inc., not Novanta Inc. as stated in the request metadata.
• Assess whether revenue and margin pressure, particularly in Vision Technologies and Laser Products, persisted beyond this quarter; note the radiology discontinuation charge.
• Check progress, remaining costs, and expected benefits of the 2016 restructuring program.
• Review debt principal, the December 2017 facility maturity, covenant headroom, and the availability and terms of refinancing.
• Separate recurring cash generation from the $2.3 million Laser Quantum dividend and one-time property-sale proceeds; monitor working capital, including higher days sales outstanding and inventory.
• Consider the effect of acquisition-related contingent consideration and the tax-rate benefit from the Laser Quantum dividend when evaluating earnings quality.